Neurocrine Q2 Revenue Surges 39% on INGREZZA Strength; Guidance Raised, Soleno Deal Closes

What happened

Neurocrine Biosciences reported second-quarter 2026 revenue of $959 million, a 39% jump from a year ago, powered by INGREZZA and CRENESSITY. INGREZZA’s full-year net sales guidance was lifted to $2.825–$2.875 billion, handily beating the prior mid-point of $2.75 billion and signaling robust volume with stable net pricing. The company also completed its acquisition of Soleno Therapeutics in May 2026, expanding its rare-disease pipeline. These results indicate the salesforce expansion is delivering, and the DOJ investigation has not yet disrupted commercial momentum. Integration costs and the cash outlay for Soleno warrant caution, but the core business is firing on all cylinders.

Implication

Investors can take comfort that INGREZZA is on track to deliver mid-teens growth without further net-price erosion, reinforcing the base-case fair value near $150. The revenue beat and guidance raise diminish the risk of a near-term gross-to-net step-down. The Soleno acquisition adds pipeline depth but introduces execution risk and initial cost pressures that must be monitored. CRENESSITY’s contribution, though not broken out, likely continued to scale, buttressing the second-leg narrative. The main overhang remains the DOJ CID; any escalation could reverse gains, but current operating momentum provides a margin of safety.

Thesis delta

The prior thesis hinged on INGREZZA volume growth without incremental net-price deterioration and CRENESSITY scaling. Q2 results and raised guidance confirm INGREZZA is exceeding the base case, strengthening the durable grower narrative. The Soleno acquisition adds a new growth avenue but introduces integration risk and near-term cost uncertainty, leaving conviction slightly tempered until deal economics become clearer.